In a report released yesterday, Soumit Roy from JonesTrading maintained a Buy rating on Forty Seven Inc (FTSV), with a price target of $30. The company’s shares opened today at $15.96.
According to TipRanks.com, Roy has 0 stars on 0-5 star ranking scale with an average return of -13.9% and a 25.0% success rate. Roy covers the Healthcare sector, focusing on stocks such as Neon Therapeutics Inc, Mirati Therapeutics, and Vascular Biogenics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Forty Seven Inc with a $27.75 average price target, implying a 73.9% upside from current levels. In a report issued on April 29, H.C. Wainwright also maintained a Buy rating on the stock with a $21 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $23.83 and a one-year low of $12.02. Currently, Forty Seven Inc has an average volume of 170.4K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Forty Seven, Inc. develops therapies that target cancer immune evasion pathways. It develops Hu5F9-G4, a monoclonal antibody against human CD47 that potentially has applications spanning multiple tumor types and treatment modalities.
